Banque Pictet & Cie SA recently announced the acquisition of new stake in SOPHiA GENETICS SA (NASDAQ:SOPH). The institutional investor has increased its shareholding in the Healthcare company by 1.14% to 2.17 million shares with purchase of 24500.0 shares. This fresh investment now brings its stake to 3.40% valued currently at $4.47 million. In addition, Principal Global Investors LLC raised its holdings by 0.38 million to 1.46 million shares. And Jennison Associates LLC has lifted its position by 0.31% or 3834.0 shares – to 1.24 million shares.
With over 0.26 million SOPHiA GENETICS SA (SOPH) shares trading Monday and a closing price of $3.00 on the day, the dollar volume was approximately $0.79 million. The shares have shown a negative half year performance of -14.53% and its price on 01/23/23 lost nearly -3.23%. Currently, there are 64.75M common shares owned by the public and among those 61.09M shares have been available to trade.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 5 analysts who have offered their price forecasts for SOPH have a consensus price objective of $8.00. The analysts have set the share’s price value over the next 12 months at a high of $12.00 and a low of $2.00. The average price target is 62.5% above its recent price level and a downside to the estimated low will see the stock lose -50.0% over that period. But an upside of 75.0% will see the stock hit the forecast high price target while median target price for the stock is $9.00.
The top 3 mutual fund holders in SOPHiA GENETICS SA are CS Invt. Fds. 2 -, T Rowe Price Health Sciences Fund, and PGIM Jennison Small Company Fund. CS Invt. Fds. 2 – owns 1.8 million shares of the company’s stock, all valued at over $3.71 million. T Rowe Price Health Sciences Fund sold 43807.0 shares to see its total holdings shrink to 0.64 million shares valued at over $1.31 million and representing 0.99% of the shares outstanding. PGIM Jennison Small Company Fund bought 8896.0 shares to bring its total holdings to over 0.44 million shares at a value of $0.91 million. PGIM Jennison Small Company Fund now owns shares totaling to 0.69% of the shares outstanding.
Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) opened at $3.14, up $0.04 from a prior closing price of $3.10. However, the script later moved the day high at 3.1500, down -3.23%. The company’s stock has a 5-day price change of -4.15% and 32.16% over the past three months. SOPH shares are trading 45.63% year to date (YTD), with the 12-month market performance down to -74.81% lower. It has a 12-month low price of $1.68 and touched a high of $14.49 over the same period. SOPH has an average intraday trading volume of 85.93K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 13.44%, 29.29%, and -14.21% respectively.
Institutional ownership of SOPHiA GENETICS SA (NASDAQ: SOPH) shares accounts for 47.00% of the company’s 64.75M shares outstanding. Mutual fund holders own 24.45%, while other institutional holders and individual stakeholders account for 6.44% and — respectively.
It has a market capitalization of $186.39M. The earnings-per-share (ttm) stands at -$1.48. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.09% over the week and 13.11% over the month.
Analysts forecast that SOPHiA GENETICS SA (SOPH) will achieve an EPS of -$0.38 for the current quarter, -$0.37 for the next quarter and -$1.35 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.38 while analysts give the company a high EPS estimate of -$0.38. Comparatively, EPS for the current quarter was -$0.3 a year ago. Earnings per share for the fiscal year are expected to decrease by -114.50%, and 9.90% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 5 brokerage firm advisors rate SOPHiA GENETICS SA (SOPH) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 4 Wall Street analysts polled rate the stock as a buy, while 1 of the 5 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the SOPH, a number of firms have released research notes about the stock. BTIG Research stated their Buy rating for the stock in a research note on January 03, 2023, with the firm’s price target at $6. Credit Suisse coverage for the SOPHiA GENETICS SA (SOPH) stock in a research note released on November 23, 2022 offered a Neutral rating with a price target of $2. Cowen was of a view on October 15, 2021 that the stock is Outperform, while Morgan Stanley gave the stock Overweight rating on August 17, 2021, issuing a price target of $24. JP Morgan on their part issued Overweight rating on August 17, 2021.
